MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why AKTS Stock advanced +0.18% Today — RQD Quant Desk Flash
$16.85 +0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $16.82
Aktis Oncology Inc. (AKTS) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $937.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $16.82 (-0.16%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTS)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY AKTS SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$18.15-17% Next Q
64
Q2 (-2Q)Grade C$15.06+4.4% Next Q
61
Q3 (-1Q)Grade C$15.73+7.1% Next Q
59
CurrentGrade D+$16.85-0.4% Hist 90D α
56
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AKTS Bull Thesis Could Fail
Even with a 56/100 (D+) score, AKTS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.57) or 200D SMA ($21.01) invalidates the momentum regime and cuts Target Base ($16.70) toward Bear Floor ($13.03).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AKTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AKTS Stock advanced +0.18% Today — RQD Quant Desk Flash
Aktis Oncology Inc. (AKTS) advanced +0.18% to $16.85, trading at 11% of its 52-week range ($14.72 – $34.19). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($14.72 – $34.19) with RSI-14 at 36.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $16.85 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $26.2M annual free cash flow.
Live AKTS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTS)
- ✓Walkthrough of AKTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AKTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.13%▼ DESCENDING CHANNEL
2026-10-30O $16.84H $17.07L $15.77C $16.85VOL 251.5K
RES: $21.98SUP: $13.78SMA50: $20.57SMA200: $21.01
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AKTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AKTS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AKTS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AKTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTS)
Health Care Rank #266 of 1016
⚔️ KURA vs AKTS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AKTS vs. KURA, ORIC, CYRX, ANRO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aktis Oncology Inc. (AKTS) ranks #266 by composite RQD confidence (56/100, grade D+) and #369 by equity capitalization ($937.2M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AKTS
ACTIVE
Aktis Oncology Inc. | D+ | 56/100 | — | — | — | +0.18% | $937.2M | Benchmark Subject |
| KURA Kura Oncology Inc. | E | 29/100 | — | — | -35.0% | -1.49% | $939.4M | /kura-vs-akts → |
| ORIC Oric Pharmaceuticals Inc. | D- | 39/100 | — | — | -33.4% | -3.33% | $931.8M | /oric-vs-akts → |
| CYRX CryoPort Inc. | D- | 38/100 | 11.8x | 47.1% | -11.5% | -1.88% | $926.4M | /cyrx-vs-akts → |
| ANRO Alto Neuroscience Inc. | D- | 38/100 | — | — | -35.0% | +0.60% | $921.0M | /anro-vs-akts → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002035832In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, AKTS closed FY2025 with $264.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $264.9M | — |
3. AKTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $16.85 (+0.18% 1D, market cap $937.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AKTS ranks #266 in composite RQD confidence.
How does AKTS compare to KURA and ORIC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KURA (Kura Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AKTS?
Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AKTS trading relative to its 50-day, 200-day, and 52-week technical levels?
AKTS last traded at $16.85 (+0.18% on volume of 245,686 shares), positioning the stock -18.08% below its 50-day simple moving average ($20.57) and -19.80% below its 200-day simple moving average ($21.01). Across its 52-week range of $14.72 to $34.19, AKTS sits at the 10.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($14.83 to $18.87).
AKTS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AKTS stock moving today?
Why AKTS Stock advanced +0.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.